GSK.L
Latest Trade
1,675.00GBpChange
-37.00(-2.16%)Volume
12,140,696Today's Range
-
1,699.2052 Week Range
-
1,770.60As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
Previous Close | 1,712.00 |
|---|---|
Open | 1,696.20 |
Volume | 12,140,696 |
3M AVG Volume | 142.50 |
Today's High | 1,699.20 |
Today's Low | 1,641.20 |
52 Week High | 1,770.60 |
52 Week Low | 1,408.80 |
Shares Out (MIL) | 4,988.72 |
Market Cap (MIL) | 83,561.13 |
Forward P/E | 14.35 |
Dividend (Yield %) | -- |
UK's MHRA Issues Drug Alert As GlaxoSmithKline Recalls All Unexpired Zantac Stock
Gsk And Lyell Immunopharma To Develop Next Generation Of Cancer Cell Therapies
Vectura Says UK Court Dismissed GSK's Claims Of Passing Off In Respect Of Sandoz's Airflusal Forspiro
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Industry
Biotechnology & Drugs
Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 18.33 |
|---|---|
Price To Sales (TTM) | 2.63 |
Price To Book (MRQ) | 23.12 |
Price To Cash Flow (TTM) | 10.30 |
Total Debt To Equity (MRQ) | 925.84 |
LT Debt To Equity (MRQ) | 645.07 |
Return on Investment (TTM) | 12.65 |
Return on Equity (TTM) | 8.20 |
GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.
GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.
Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
UK shares were steady on Monday as investors largely opted for a wait-and-watch approach amid simmering U.S.-China trade tensions and Brexit worries, and a lack of significant corporate news.
GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
GlaxoSmithKline and AstraZeneca will each present trial data on a promising new class of drugs against ovarian cancer on Saturday as Britain's top drugmakers compete to burnish their oncology credentials.
Microsoft Corp said on Thursday it has nominated GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley to its board of directors.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their nicotine addiction.
* Fasenra gets U.S. FDA orphan drug status (Adds details on Breztri data)
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business.
GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...
British drugmaker GlaxoSmithKline Plc said on Thursday its long-lasting two-drug regimen to treat HIV met the main goal of a late-stage study.
AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.
British drugmaker GlaxoSmithKline <GSK.L> is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.
British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.
GlaxoSmithKline <GSK.L> beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.